JUSTICE DELAYED, JUSTICE DENIED: SUPREME COURT STEP IN AFTER KERALA HIGH COURT ADJOURNS LIFE-SAVING DRUGS PLEA 57 TIMES
Apex Court Initiates Suo Motu Action Over Systematic Failure to Guarantee Affordable Patented Healthcare
Tragic Death of Patient Highlights Regulatory Paralysis and Judicial Procrastination in Enforcing Constitutional Guarantees
By Legal Editor
New Delhi: July 18, 2026:
On July 17, 2026, the Supreme Court of India took historical suo motu cognisance of an incredibly tragic intersection of judicial delay and economic barriers to healthcare. The case, titled In Re: Access to Life-Saving Medicines and Judicial Expediency in Article 21 Matters, was triggered by media reports revealing that a writ petition before the Kerala High Court had been adjourned 57 times while the petitioner—a critically ill patient needing expensive, imported life-saving medicines—waited in vain. By the time the state apparatus moved to procure the drug, and before the court could settle the underlying legal entitlements, the patient had passed away.
A three-judge Bench comprising Chief Justice of India Surya Kant, Justice Joymalya Bagchi, and Justice V. Mohana expressed profound concern over how systematic operational gridlocks dismantle constitutional safety nets. While the case began as an individual's struggle to survive, it has thrown the spotlight onto a larger national failure: the non-invocation of emergency economic provisions within intellectual property law to curb the pricing of patented medicines. This analytical article unpacks the constitutional, statutory, and administrative regimes discussed in these proceedings, mapping the tension between international patent protections and the fundamental right to survive.
The Constitutional Pillar: Expanding Article 21 and the Obligation of the State
The Supreme Court’s intervention rests directly upon Article 21 of the Constitution of India, which mandates that "No person shall be deprived of his life or personal liberty except according to procedure established by law." Over the past four decades, the Indian judiciary has aggressively expanded the definition of "life" beyond mere physical existence, establishing that it encompasses human dignity, access to a clean environment, and crucially, the right to health.
The Evolution of Healthcare Jurisprudence
The apex court has repeatedly tied the right to medical care to the state's welfare duties. In landmark cases such as Parmanand Katara v. Union of India (1989), the court ruled that preserving human life is of paramount importance, declaring that every medical professional has an unshakeable duty to provide immediate aid. This was further solidified in Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996), where the Supreme Court explicitly held that the failure of a government hospital to provide timely emergency medical treatment amounts to a direct violation of Article 21.
When a petition concerning life-saving medicines is adjourned 57 times, the "procedure established by law" itself becomes a lethal bottleneck. As CJI Surya Kant observed during the hearing, the court was initially hesitant to interfere while the Kerala High Court was seized of the matter, but administrative inertia forced their hand. By treating judicial delay as an existential threat to Article 21, the Supreme Court has sent a clear message: procedural expediency is not an administrative courtesy; it is a core component of the fundamental right to life.
The Statutory Failure: Monopolies vs. Public Health under the Patents Act, 1970
While the constitutional failure in this case stems from procedural delays, the systemic economic crisis is rooted in the implementation of the Patents Act, 1970. During the proceedings, Senior Advocate Anand Grover intervened to highlight a stark reality: since India became fully compliant with the World Trade Organization's (WTO) TRIPS Agreement in 2005, the domestic pharmaceutical market has seen an influx of highly expensive, patented foreign molecules.
Because global pharmaceutical conglomerates hold strict product patents, they maintain exclusive marketing rights that block local generic manufacturers from introducing low-cost alternatives. This leaves impoverished or middle-class patients entirely reliant on imported drugs, which frequently carry exorbitant price tags.
┌────────────────────────────────────────┐
│ Patents Act, 1970 Enforcements │
└───────────────────┬────────────────────┘
│
┌─────────────────────────┼────────────────────────┐
▼ ▼ ▼
Section 84 Section 92 Section 100
(Third-Party Requests (Govt. Emergency Suo (Government Use of
After 3-Year Windows) Motu Declarations) Patented Inventions)
The Shield of Compulsory Licensing
To prevent patent regimes from turning into absolute monopolies at the expense of human lives, the Patents Act contains built-in checks and balances. The primary tool is Compulsory Licensing (CL), which allows the state to authorize third parties to manufacture and sell generic versions of a patented product without the patent holder's consent, provided certain public-interest criteria are met.
Section 84: Allows any interested person to apply to the Controller of Patents for a compulsory license after three years from the date of the patent grant. The applicant must prove that the reasonable requirements of the public have not been satisfied, that the invention is unavailable at an affordable price, or that the patent is not being "worked" within the territory of India.
Section 92: Grants the Central Government suo motu powers to issue a compulsory license at any time following a notification in the official gazette. This can be triggered by circumstances of a national emergency, extreme urgency, or in instances of public non-commercial use.
Section 100: Empowers the government to use any patented invention for its own purposes, effectively bypassing exclusivity to meet public healthcare needs.
The Reality of Under-Utilization
Despite these robust statutory tools, Senior Advocate Grover pointed out that the government has been incredibly hesitant to use them. In over two decades of the post-2005 product patent era, India has granted exactly one compulsory license.
That single license was issued in 2012, when the Controller General of Patents allowed Natco Pharma to manufacture a generic version of Bayer Corporation's advanced kidney and liver cancer drug, Sorafenib Tosylate (Nexavar). Natco brought the price of the drug down by over 99%—from roughly ₹2.8 lakh per month to less than ₹9,000 per month—demonstrating the massive impact of the provision.
The historical hesitation to issue subsequent compulsory licenses is largely driven by geopolitical trade pressures and fears of alienating global pharmaceutical innovation investments. However, as the tragic case from Kerala demonstrates, this regulatory reluctance forces citizens to depend on discretionary, ad-hoc state interventions—like importing a drug on a case-by-case basis—rather than benefiting from a predictable, systemic framework of affordable generic production.
Structural Reforms and the Path Forward
Recognizing the broad, systemic nature of the crisis, the Kerala High Court had previously converted the individual patient’s petition into a wider suo motu public interest litigation titled In Re: Exorbitant Pricing of Life Saving Patented Medicines. The Supreme Court has now widened this lens to a national scale.
Resolving this crisis requires structural changes on two distinct fronts:
1. Judicial Expediency and Triage Mechanisms
Courts must establish immediate administrative triage rules for cases involving terminal illnesses or urgent access to life-saving healthcare. A petition asserting a violation of Article 21 due to a lack of affordable medicine cannot be treated like a standard civil or commercial dispute. Adjournments in these matters should be strictly restricted by institutional mandates, and high courts must deploy dedicated fast-track paths to rule on state financial aid or emergency regulatory interventions before a patient's condition becomes terminal.
2. Streamlining the Compulsory Licensing Pipeline
The Central Government must design an objective, predictable policy framework to trigger Sections 92 and 100 of the Patents Act. Instead of treating compulsory licensing as an extreme, confrontational measure, it should be utilized as a standard regulatory mechanism to counter monopolistic pricing on essential medications. When a critical drug is entirely out of reach for the general public, the state has a constitutional obligation under Article 21 to override corporate patent protections in favor of human survival.
Detailed Legal FAQ Index
This searchable index breaks down the primary statutory and constitutional tenets underpinning the legal debate surrounding access to patented medicines in India.
[CR-01] Constitutional Right to Healthcare
Question: How does the Constitution of India guarantee access to affordable life-saving medicines?
Answer: While the Constitution does not contain an explicit text guaranteeing a "Right to Health," the Supreme Court of India has consistently read the right to health, medical care, and affordable treatment into Article 21 (The Right to Life and Personal Liberty). Under this framework, the state is under a constitutional mandate to build up public health systems, ensure access to necessary treatments, and step in when extreme financial barriers prevent citizens from obtaining life-saving care.
[CL-02] Definition of Compulsory Licensing
Question: What is a Compulsory License under Indian Patent Law, and who issues it?
Answer: A Compulsory License (CL) is an administrative authorization granted by the Controller General of Patents, Designs and Trade Marks. It allows a third party (such as a local generic drug manufacturer) to produce, market, and distribute a patented invention without the permission of the patent owner. The mechanism is designed to break up market monopolies, lower prices, and ensure that essential items remain accessible during public health crises.
[CL-03] Statutory Grounds Under Section 84
Question: Under what specific conditions can an independent manufacturer apply for a Compulsory License under Section 84?
Answer: An application for a compulsory license can be submitted under , but only after a period of three years has passed from the date the patent was originally granted. The applicant must demonstrate that at least one of the following three conditions is met:
The reasonable requirements of the public regarding the patented invention have not been fulfilled or satisfied.
The patented invention is not made available to the general public at a reasonably affordable price.
The patented invention is not being manufactured or "worked" within the territory of India.
[CL-04] Government Emergency Powers Under Section 92
Question: How do the government's emergency powers under Section 92 differ from standard compulsory licensing?
Answer: Under Section 84, the process is driven by an application from a third party and is subject to full administrative hearings. In contrast, Section 92 grants the Central Government suo motu authority to issue a compulsory license at any point without waiting for the standard three-year window. This power can be executed via an official gazette notification under circumstances of a national emergency, extreme urgency, or for public non-commercial use. Once the notification is published, the Controller can grant licenses to applicants immediately, skipping the protracted negotiation phases.
[CL-05] Historic Precedents in India
Question: Has India ever successfully issued a Compulsory License for a patented drug?
Answer: Yes. The first and only compulsory license in Indian legal history was issued by the Controller of Patents on March 9, 2012, to the domestic firm Natco Pharma for a patented cancer drug called Sorafenib Tosylate (Nexavar), which was held by Bayer Corporation. Natco successfully argued that Bayer’s drug was completely unaffordable (costing roughly ₹2.8 lakh per month) and imported in completely inadequate quantities. Following the grant of the license, Natco introduced a generic alternative priced at approximately ₹8,800 per month, while paying a fixed percentage of royalties back to Bayer.
[CL-06] International Trade Compliance
Question: Does India's use of Compulsory Licensing violate international treaties or global intellectual property laws?
Answer: No. India's Compulsory Licensing framework is fully compliant with international law. The World Trade Organization's (WTO) TRIPS Agreement explicitly recognizes the sovereign right of member nations to issue compulsory licenses. This flexibility was further clarified by the Doha Declaration on the TRIPS Agreement and Public Health (2001), which affirmed that the intellectual property pact should not prevent governments from taking measures to protect public health, explicitly confirming that each member country has the absolute freedom to determine what constitutes a national emergency or extreme urgency.
Analytical Summary of Key Statutory Provisions
Provision — Primary Authority — Act / Framework — Core Functional Role
Article 21 — Supreme Court / High Courts — Constitution of India — Guarantees the fundamental Right to Life, interpreted to encompass timely judicial access and affordable medical care.
Section 84 — Controller General of Patents — Patents Act, 1970 — Provides a pathway for private third-party manufacturers to challenge patent exclusivity 3 years after its grant based on high pricing or low supply.
Section 92 — Central Government — Patents Act, 1970 — Enables suo motu executive declarations to bypass patent rights instantly during national emergencies or public health crises.
Section 100 — Union Ministry / State Organs — Patents Act, 1970 — Empowers government departments or authorized third parties to directly use patented inventions for public purposes.
Article 31 — World Trade Organization — TRIPS Agreement — International framework establishing global guardrails for domestic compulsory licensing without patentee consent during crises.